Effect of somatostatin (SRIF) on plasma glucose and insulin response to glucagon in liver cirrhosis. 1979

L Altomonte, and A V Greco, and G Ghirlanda, and A G Rebuzzi, and R Manna, and A Bertoli

The present study was performed in order to evaluate the plasma glucose pattern in cirrhotic patients who, in the course of a continuous somatostatin infusion (500 microgram/h), were given pulses of glucagon (1 mg i.v.). In normal as well as in cirrhotic subjects somatostatin infusion provoked a marked reduction of the IRI plasma level and this was uninfluenced by subsequent glucagon administration. The rise in plasma glucose level in response to i.v. glucagon administration during somatostatin infusion was less marked in cirrhotics compared to normal subjects. This can be attributed to a variety of factors such as reduced number of liver cells or quantitative or qualitative changes of the liver cell glucagon receptors. Glucagon does not seem to contribute to the pathogenesis of carbohydrate intolerance in liver cirrhosis.

UI MeSH Term Description Entries
D007328 Insulin A 51-amino acid pancreatic hormone that plays a major role in the regulation of glucose metabolism, directly by suppressing endogenous glucose production (GLYCOGENOLYSIS; GLUCONEOGENESIS) and indirectly by suppressing GLUCAGON secretion and LIPOLYSIS. Native insulin is a globular protein comprised of a zinc-coordinated hexamer. Each insulin monomer containing two chains, A (21 residues) and B (30 residues), linked by two disulfide bonds. Insulin is used as a drug to control insulin-dependent diabetes mellitus (DIABETES MELLITUS, TYPE 1). Iletin,Insulin A Chain,Insulin B Chain,Insulin, Regular,Novolin,Sodium Insulin,Soluble Insulin,Chain, Insulin B,Insulin, Sodium,Insulin, Soluble,Regular Insulin
D008103 Liver Cirrhosis Liver disease in which the normal microcirculation, the gross vascular anatomy, and the hepatic architecture have been variably destroyed and altered with fibrous septa surrounding regenerated or regenerating parenchymal nodules. Cirrhosis, Liver,Fibrosis, Liver,Hepatic Cirrhosis,Liver Fibrosis,Cirrhosis, Hepatic
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D001786 Blood Glucose Glucose in blood. Blood Sugar,Glucose, Blood,Sugar, Blood
D005934 Glucagon A 29-amino acid pancreatic peptide derived from proglucagon which is also the precursor of intestinal GLUCAGON-LIKE PEPTIDES. Glucagon is secreted by PANCREATIC ALPHA CELLS and plays an important role in regulation of BLOOD GLUCOSE concentration, ketone metabolism, and several other biochemical and physiological processes. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1511) Glucagon (1-29),Glukagon,HG-Factor,Hyperglycemic-Glycogenolytic Factor,Proglucagon (33-61),HG Factor,Hyperglycemic Glycogenolytic Factor
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D013004 Somatostatin A 14-amino acid peptide named for its ability to inhibit pituitary GROWTH HORMONE release, also called somatotropin release-inhibiting factor. It is expressed in the central and peripheral nervous systems, the gut, and other organs. SRIF can also inhibit the release of THYROID-STIMULATING HORMONE; PROLACTIN; INSULIN; and GLUCAGON besides acting as a neurotransmitter and neuromodulator. In a number of species including humans, there is an additional form of somatostatin, SRIF-28 with a 14-amino acid extension at the N-terminal. Cyclic Somatostatin,Somatostatin-14,Somatotropin Release-Inhibiting Hormone,SRIH-14,Somatofalk,Somatostatin, Cyclic,Somatotropin Release-Inhibiting Factor,Stilamin,Somatostatin 14,Somatotropin Release Inhibiting Factor,Somatotropin Release Inhibiting Hormone
D013268 Stimulation, Chemical The increase in a measurable parameter of a PHYSIOLOGICAL PROCESS, including cellular, microbial, and plant; immunological, cardiovascular, respiratory, reproductive, urinary, digestive, neural, musculoskeletal, ocular, and skin physiological processes; or METABOLIC PROCESS, including enzymatic and other pharmacological processes, by a drug or other chemical. Chemical Stimulation,Chemical Stimulations,Stimulations, Chemical

Related Publications

L Altomonte, and A V Greco, and G Ghirlanda, and A G Rebuzzi, and R Manna, and A Bertoli
January 1970, Rivista critica di clinica medica,
L Altomonte, and A V Greco, and G Ghirlanda, and A G Rebuzzi, and R Manna, and A Bertoli
December 1974, The Journal of clinical endocrinology and metabolism,
L Altomonte, and A V Greco, and G Ghirlanda, and A G Rebuzzi, and R Manna, and A Bertoli
August 1979, Journal of applied physiology: respiratory, environmental and exercise physiology,
L Altomonte, and A V Greco, and G Ghirlanda, and A G Rebuzzi, and R Manna, and A Bertoli
January 1984, Acta chirurgica Scandinavica,
L Altomonte, and A V Greco, and G Ghirlanda, and A G Rebuzzi, and R Manna, and A Bertoli
July 1985, Diabetologia,
L Altomonte, and A V Greco, and G Ghirlanda, and A G Rebuzzi, and R Manna, and A Bertoli
October 1980, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme,
L Altomonte, and A V Greco, and G Ghirlanda, and A G Rebuzzi, and R Manna, and A Bertoli
January 1981, Journal of endocrinological investigation,
L Altomonte, and A V Greco, and G Ghirlanda, and A G Rebuzzi, and R Manna, and A Bertoli
September 1983, The Indian journal of medical research,
L Altomonte, and A V Greco, and G Ghirlanda, and A G Rebuzzi, and R Manna, and A Bertoli
September 1978, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme,
L Altomonte, and A V Greco, and G Ghirlanda, and A G Rebuzzi, and R Manna, and A Bertoli
November 1983, American journal of obstetrics and gynecology,
Copied contents to your clipboard!